Table 1. Neoadjuvant Checkpoint Inhibitor Trials in malignant pleural mesothelioma (MPM) discussed in this article.

Agent	Phase	Identifier	Target	Number of patients	Status	Reference
Nivolumab; ipilimumab	II/III	NCT03918252	Anti-PD-1; Anti-CTLA4	30	Not yet recruiting
Atezolizumab	I	NCT03228537	Anti-PD-L1	28	Recruiting	(31)
Pembrolizumab	I	NCT02707666	Anti-PD-1	15	Recruiting	(38)
Pembrolizumab	I	NCT02959463	Anti-PD-1	24	Recruiting
Tremelimumab; durvalumab	II	NCT02592551	Anti-CTLA4; Anti-PD-L1	20	Recruiting